Furthermore, applying these approaches in the context of cancer immunotherapy, we demonstrated that CyTOF-based T cell metrics can reflect significant changes during active immunotherapy with the anti–CTLA-4 checkpoint inhibitor, ipilimumab, and the cancer-specific vaccine, GVAX, and associate with clinical endpoints. Here, CTLA4 is linked to cancer.